COVID-19 Infection During Pregnancy: A Closer Look at the Risk of Stillbirth

By Staff Writer

November 6, 2023

A Groundbreaking Study

A recent Nordic research study has shed light on the potential increased risk of stillbirth among pregnant women infected with COVID-19. This comprehensive study, the largest of its kind, analysed data from 389,949 births across Norway, Sweden and Denmark. The findings revealed a 2.4 times higher risk of stillbirth among women who contracted COVID-19 during pregnancy.


Understanding the Risks

While stillbirth remains a rare occurrence, the study found that the absolute risk was 2.3 per 100,000 follow-up days for pregnant women without COVID-19. In contrast, the risk was 5.8 per 100,000 follow-up days for those who contracted the virus during pregnancy. Notably, the risk of stillbirth was highest within the first two weeks of infection.

COVID-19 and Pregnancy Risk

The study also discovered that the risk of stillbirth varied based on the COVID-19 variant that the pregnant woman tested positive for. The risk was highest during the period when the Delta variant was dominant. However, due to changes in COVID-19 testing recommendations, the risk associated with current variants remains unknown.

In light of these findings, the Norwegian Institute of Public Health recommends pregnant women get vaccinated against COVID-19 during their second or third trimester. This recommendation is based on research showing a certain increased risk of serious illness or complications among pregnant women infected by COVID-19, with no connected risk for the mother, child, or pregnancy among those vaccinated.

Reference url

Recent Posts

oral health Africa
    

Oral Health in Africa: Promoting Collaborative Solutions

🦷 Is oral health taking a back seat in public health discussions in Africa?

A new article reveals alarming statistics about the high prevalence of untreated dental diseases across the continent and a critical shortage of oral health professionals. It emphasizes the urgent need for collaborative action among healthcare providers and policy-makers to integrate oral health into broader public health frameworks.

Discover how strengthening partnerships can pave the way for improved health outcomes and resource allocation in oral health.

#SyenzaNews #globalhealth #HealthEconomics

tislelizumab NSCLC treatment
        

Early Benefit Assessment of Tislelizumab NSCLC Treatment: Insights and Implications

🧐 How is the evolving treatment landscape for NSCLC affecting patient access to tislelizumab?

The German Federal Joint Committee (G-BA) has launched an early benefit assessment for tislelizumab as a second-line treatment for adults with advanced NSCLC. This assessment notably focuses on PD-L1 negative patients and highlights the need for additional data to substantiate its value amidst a shifting emphasis on first-line immunotherapy.

Explore the nuances of this assessment and its implications for future research and market access in the full article.

#SyenzaNews #oncology #MarketAccess

colorectal cancer screening
    

Advances in Colorectal Cancer Screening: Access and Cost

🚀 Is blood-based screening redefining colorectal cancer detection?

The Shield blood test offers a non-invasive alternative to colonoscopy—boosting screening uptake, but raising questions around effectiveness and value.

🔍 Discover how this innovation could reshape patient care, payer strategy, and health system costs.

#SyenzaNews #HealthcareInnovation #CostEffectiveness #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.